Table 1:
Characteristics of breast cancer patients diagnosed 2007-2013, according to bipolar and psychotic disorder status
| Bipolar and psychotic disorder diagnosed | ||||||||
|---|---|---|---|---|---|---|---|---|
| Covariate | Level | All N=21,894 | No N=20,635 (94.2%) | Yes N=1,259 (5.8%) | p value* |
|||
| Age at Diagnosis | 68-74 | 9,308 | 42.5% | 8,732 | 42.3% | 576 | 45.8% | 0.006 |
| 75-84 | 9,659 | 44.1% | 9,133 | 44.3% | 526 | 41.8% | ||
| 85-94 | 2,831 | 12.9% | 2,685 | 13.0% | 146 | 11.6% | ||
| 95+ | 96 | 0.4% | 85 | 0.4% | 11 | 0.9% | ||
| Race | Asian | a-- | a-- | 910 | 4.4% | a-- | a-- | 0.19 |
| Black | 1,315 | 6.0% | 1,233 | 6.0% | 82 | 6.5% | ||
| Other | a-- | a-- | 140 | 0.7% | a-- | a-- | ||
| White | 19,480 | 89.0% | 18,352 | 88.9% | 1,128 | 89.6% | ||
| Ethnicity | Hispanic | 1,166 | 5.3% | 1,090 | 5.3% | 76 | 6.0% | 0.25 |
| Non-Hispanic | 20,728 | 94.7% | 19,545 | 94.7% | 1,183 | 94.0% | ||
| Rurality | Metro | 18,053 | 82.5% | 16,957 | 82.2% | 1,096 | 87.1% | <.001 |
| Non-metro, non-rural | 3,361 | 15.4% | 3,220 | 15.6% | 141 | 11.2% | ||
| Rural | a-- | a-- | a-- | a-- | a-- | a-- | ||
| Unknown | a-- | a-- | a- | a-- | a-- | a-- | ||
| Year of Diagnosis | 2007 | 1,961 | 9.0% | 1,855 | 9.0% | 106 | 8.4% | 0.90 |
| 2008 | 2,968 | 13.6% | 2,801 | 13.6% | 167 | 13.3% | ||
| 2009 | 3,144 | 14.4% | 2,954 | 14.3% | 190 | 15.1% | ||
| 2010 | 3,131 | 14.3% | 2,953 | 14.3% | 178 | 14.1% | ||
| 2011 | 3,300 | 15.1% | 3,119 | 15.1% | 181 | 14.4% | ||
| 2012 | 3,492 | 15.9% | 3,279 | 15.9% | 213 | 16.9% | ||
| 2013 | 3,898 | 17.8% | 3,674 | 17.8% | 224 | 17.8% | ||
| Stage at Diagnosis | I | 13,194 | 60.3% | 12,503 | 60.6% | 691 | 54.9% | <.001 |
| II | 6,534 | 29.8% | 6,119 | 29.7% | 415 | 33.0% | ||
| III | 1,516 | 6.9% | 1,397 | 6.8% | 119 | 9.5% | ||
| IV | a-- | a-- | 195 | 0.9% | a-- | a-- | ||
| Unknown | a-- | a-- | 421 | 2.0% | a-- | a-- | ||
| Receptor Status | ER+PR+ | 18,789 | 85.8% | 17,718 | 85.9% | 1,071 | 85.1% | 0.43 |
| ER+PR- | 3,105 | 14.2% | 2,917 | 14.1% | 188 | 14.9% | ||
| Endocrine Therapy Class | AIs | 13,659 | 62.4% | 12,889 | 62.5% | 770 | 61.2% | <.001 |
| Both | 1,903 | 8.7% | 1,819 | 8.8% | 84 | 6.7% | ||
| None | 4,382 | 20.0% | 4,074 | 19.7% | 308 | 24.5% | ||
| SERMs | 1,950 | 8.9% | 1,853 | 9.0% | 97 | 7.7% | ||
| Adjusted NCI Comorbidity | Mean (Median) | 2.1 (2.0) | 2.0 | 2.0 | 3.1 | 3.0 | <.001 | |
| Function-related Indicators | 0 | 12,921 | 59.0% | 12,741 | 61.7% | 180 | 14.3% | <.001 |
| 1 | 5,159 | 23.6% | 4,718 | 22.9% | 441 | 35.0% | ||
| 2 | 1,995 | 9.1% | 1,722 | 8.3% | 273 | 21.7% | ||
| 3+ | 1,819 | 8.3% | 1,454 | 7.0% | 365 | 29.0% | ||
| Anxiety Disorder | 2,086 | 9.5% | 1,673 | 8.1% | 413 | 32.8% | <.001 | |
| Dementia Disorder | 1,017 | 4.6% | 742 | 3.6% | 275 | 21.8% | <.001 | |
| Substance Use Disorder | 1,006 | 4.6% | 846 | 4.1% | 160 | 12.7% | <.001 | |
| Number of Medicationsd | 0-3 | 6,617 | 30.2% | 6,474 | 31.4% | 143 | 11.4% | <.001 |
| 4-8 | 10,358 | 47.3% | 9,833 | 47.7% | 525 | 41.7% | ||
| 9+ | 4,919 | 22.5% | 4,328 | 21.0% | 591 | 46.9% | ||
| Number of Pharmacy Visits | 0-1 | 2,463 | 11.2% | 2,414 | 11.7% | 49 | 3.9% | <.001 |
| 2-4 | 5,755 | 26.3% | 5,602 | 27.2% | 153 | 12.1% | ||
| 5-10 | 9,799 | 44.8% | 9,234 | 44.7% | 565 | 44.9% | ||
| 11+ | 3,877 | 17.7% | 3,385 | 16.4% | 492 | 39.1% | ||
| MRCI-A Route Complexity | 0-1 | 12,006 | 54.8% | 11,488 | 55.7% | 518 | 41.1% | <.001 |
| 2-4 | 7,252 | 33.1% | 6,789 | 32.9% | 463 | 36.8% | ||
| 5+ | 2,636 | 12.0% | 2,358 | 11.4% | 278 | 22.1% | ||
| Combined Medication & Visit Score | No Meds | 1,207 | 5.5% | 1,182 | 5.7% | 25 | 2.0% | <.001 |
| 1-3 Meds | 1,132 | 5.2% | 1,115 | 5.4% | 17 | 1.3% | ||
| 4+ Meds or 2+ Visits | 4,402 | 20.1% | 4,294 | 20.8% | 108 | 8.6% | ||
| 4+ Meds & 2+ Visits | 15,153 | 69.2% | 14,044 | 68.1% | 1,109 | 88.1% | ||
| Out-Of-Pocket Medication Cost | $0 < $1 | 2,266 | 10.3% | 2,007 | 9.7% | 259 | 20.6% | <.001 |
| $1 < $50 | 5,882 | 26.9% | 5,596 | 27.1% | 286 | 22.7% | ||
| $50 < $500 | 11,874 | 54.2% | 11,353 | 55.0% | 521 | 41.4% | ||
| $500+ | 1,872 | 8.6% | 1,679 | 8.1% | 193 | 15.3% | ||
| Number Who Initiated | 17,512 | 80.0% | 16,561 | 80.3% | 951 | 75.5% | <.001 | |
| Days to Initiation | Mean (Median) | 156.6 (120.0) | 156.7 | 120.0 | 156.6 | 120.0 | 0.68 | |
| Number Who Discontinued | 4,503 | 25.7% | 4,248 | 255 | ||||
| bDays to Discontinuation | Mean (Median) | 701.5 (521.0) | 704.8 | 523.0 | 647.1 | 458.0 | 0.28 | |
| Number with 1+ Years | 14,517 | 66.3% | 13,739 | 778 | ||||
| cAverage Adherence | Mean (Median) | 0.84 (0.90) | 0.84 | 0.91 | 0.84 | 0.91 | 0.23 | |
| Follow-up Days | Mean (Median) | 1377.9 (1280.0) | 1,383.3 | 1,280.0 | 1,288.3 | 1,157.0 | <.001 | |
| Number Censored at Death | 1,376 | 6.3% | 1,242 | 6.0% | 134.0 | 10.6% | <.001 | |
“Combined Medication & Visit” variable created from each variable’s significant response levels in separate adjusted models (Appendix 2).
a
Values under 11 and nearest strata censored to maintain confidentiality.
b
Discontinuation analysis censored after five years continuous use.
c
Adherence measured with the proportion of days covered (PDC), for patients with one or more years of observation with over half of this time outside hospitals and skilled nursing facilities.
d
Medication variables describe utilization in the four months prior to breast cancer diagnosis.
*
Parametric p value calculated by chi-square test, Wilcoxon for continuous variables.